Provided by Tiger Trade Technology Pte. Ltd.

Citius Pharmaceuticals, Inc.

0.7090
+0.01802.60%
Post-market: 0.6953-0.0137-1.93%19:51 EST
Volume:245.31K
Turnover:171.91K
Market Cap:15.86M
PE:-0.24
High:0.7185
Open:0.7100
Low:0.6711
Close:0.6910
52wk High:2.48
52wk Low:0.6300
Shares:22.38M
Float Shares:18.81M
Volume Ratio:0.45
T/O Rate:1.30%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.9159
EPS(LYR):-5.9739
ROE:-47.85%
ROA:-17.68%
PB:0.20
PE(LYR):-0.12

Loading ...

Citius Pharmaceuticals reports first revenue of $3.9 mln

Reuters
·
Feb 13

Citius Oncology Inc. posts Q1 net loss of USD 5.53 million, down 17 percent

Reuters
·
Feb 13

Citius Pharma Q1 stock-based compensation expense rises to USD 3.56 million, up 97%

Reuters
·
Feb 13

Citius Pharmaceuticals Q1 Basic EPS USD -0.38

THOMSON REUTERS
·
Feb 13

Citius Oncology Signs Exclusive Distribution Agreement With Uniphar for LYMPHIR in Europe

Reuters
·
Feb 11

Citius Oncology Expands International Distribution of Lymphir™ to European Union Through Exclusive Agreement With Uniphar

THOMSON REUTERS
·
Feb 11

Citius Oncology Inc. Files Information Statement Detailing Authorized Corporate Actions

Reuters
·
Jan 30

Citius Oncology Inc. Files Draft Information Statement Outlining Authorized Corporate Actions

Reuters
·
Jan 21

Dow Gains Over 100 Points; US Jobless Claims Decline

Benzinga
·
Dec 24, 2025

Citius Pharma Q4 EPS $(0.11) Beats $(0.43) Estimate

Benzinga
·
Dec 24, 2025

Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update

Dow Jones
·
Dec 24, 2025

Citius Oncology posts FY cash balance of USD 3.9 million and accumulated deficit of USD 64.0 million

Reuters
·
Dec 24, 2025

Citius Oncology Announces Warrant and Share Issuance in $18 Million Offering

Reuters
·
Dec 11, 2025

Citius Oncology Sells Shares and Warrants in $18 Million Private Placement

Reuters
·
Dec 09, 2025

Citius Oncology Inc - Proceeds Support Launch of Lymphir for Cutaneous T-Cell Lymphoma

THOMSON REUTERS
·
Dec 09, 2025

Citius Oncology Inc - to Purchase 1,284,404 Shares of Common Stock at $1.09 per Share in Direct Offering

THOMSON REUTERS
·
Dec 09, 2025

BRIEF-Citius Oncology Expands Lymphir Distribution To Turkey And Middle East Countries

Reuters
·
Dec 04, 2025

Citius Oncology Expands Lymphir™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement With Er-Kim

THOMSON REUTERS
·
Dec 04, 2025

Citius Pharmaceuticals Highlights Oncology Pipeline and LYMPHIR Launch in New Corporate Presentation

Reuters
·
Dec 02, 2025

Citius Oncology Announces U.S. Commercial Launch of Lymphir™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (Ctcl)

THOMSON REUTERS
·
Dec 02, 2025